HIV protease inhibitors

Publication number: CN1131942

Publication date: 1996-09-25

Inventor: DRESSMAN B A (US); FRITZ J E (US); HAMMOND M (US)

Applicant: AGOURON PHARMACEUTICALS INS (US)

Classification:

- International: ***C07D295/20; A61K31/00; A61K31/165; A61K31/40; A61K31/403; A61K31/404; A61K31/435; A61K31/4353; A61K31/4365; A61K31/4427; A61K31/4433; A61K31/445; A61K31/4465; A61K31/47; A61K31/472; A61K31/4725; A61K31/4738; A61K31/4743; A61K31/495; A61K31/535; A61K31/5375; A61K31/675; A61P31/00; A61P31/12; A61P31/18; A61P43/00; C07C237/42; C07C323/42; C07C323/60; C07D207/16; C07D209/08; C07D211/60; C07D211/62; C07D215/48; C07D215/50; C07D217/02; C07D217/06; C07D217/26; C07D401/06; C07D401/12; C07D401/14; C07D403/14; C07D409/12; C07D417/12; C07D495/04; C07F9/12; C07F9/62; C07K5/00;*** **C07D295/00; A61K31/00; A61K31/165; A61K31/40; A61K31/403; A61K31/435; A61K31/4353; A61K31/4427; A61K31/445; A61K31/4465; A61K31/47; A61K31/472; A61K31/4738; A61K31/495; A61K31/535; A61K31/5375; A61K31/675; A61P31/00; A61P43/00; C07C237/00; C07C323/00; C07D207/00; C07D209/00; C07D211/00; C07D215/00; C07D217/00; C07D401/00; C07D403/00; C07D409/00; C07D417/00; C07D495/00; C07F9/00; C07K5/00;** (IPC1-7): C07D217/26; C07D401/06; C07D495/04; C07F9/62

- European: C07C237/42; C07C323/60; C07D207/16; C07D209/08; C07D211/60; C07D215/48; C07D215/50; C07D217/02; C07D217/26; C07D401/06; C07D401/12; C07D403/14; C07D409/12; C07D417/12; C07D495/04; C07F9/62

Application number: CN19941093534 19941007

Priority number(s): US19930133543 19931007; US19940190764 19940202; US19930133696 19931007

Also published as:

WO9509843 (A1)
EP0722439 (A1)
US5827891 (A1)
US5827859 (A1)
OA10718 (A)
JP11310573 (A)
FI961449 (A)
EP0722439 (A0)
EE9600091 (A)
AP600 (A)
EP0722439 (B1)
SK284116B (B6)
SK284115B (B6)
RU2139280 (C1)
RO119363 (B1)
PL185647B (B1)
NO307050B (B1)
FI114794B (B)
ES2236849T (T3)
ES2181725T (T3)
DE69434214T (T2
CZ290417 (B6)
CN1195737C (C)
BG62567 (B1)
AU694746B (B2)

less <<

Abstract not available for CN1131942

Abstract of corresponding document: **US5827891**

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HI\ protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known t cause AIDS.